A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash (MATER)
A Phase II Trial Assessing Metronidazol Actavis 1% Topical Cream in the Prevention and Treatment of Erlotinib Associated Rash
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Goeteborg, Sweden, 41345
-
Lund, Sweden, 22185
-
Malmoe, Sweden, 20502
-
Stockholm, Sweden, S-14186
-
Umea, Sweden, S-901 85
-
Vaxjo, Sweden, 35185
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- non-small cell lung cancer
- eligible to start treatment with erlotinib
Exclusion Criteria:
- hypersensitivity to metronidazole
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Prevention (Erlotinib + Metronidazole Actavis)
Participants will receive erlotinib orally daily.
Metronidazole actavis treatment will be initiated at the same day as the start of erlotinib.
Metronidazole actavis 1% topical cream will be applied on the right side of the face and chest twice daily for 4 weeks.
Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
|
Participants will receive erlotinib 150 milligrams (mg) orally daily for 4 weeks.
Other Names:
Metronidazole actavis 1% topical cream will be applied on the face and chest twice daily for 4 weeks.
Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
|
|
Experimental: Treatment (Erlotinib + Metronidazole Actavis)
Participants will receive erlotinib orally daily.
Metronidazole actavis treatment will be initiated when participants develop rash.
Metronidazole actavis 1% topical cream will be applied on the right side of the face and chest twice daily for 4 weeks.
Left side of the face and chest was treated according to local standard procedures (ie, with non-active moisturizing cream).
|
Participants will receive erlotinib 150 milligrams (mg) orally daily for 4 weeks.
Other Names:
Metronidazole actavis 1% topical cream will be applied on the face and chest twice daily for 4 weeks.
Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Erlotinib Associated Rash Stratified by Severity Grade at Week 2
Time Frame: After 2 weeks of metronidazole treatment
|
Severity of the rash was evaluated semi-quantitatively using the scale of Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Grade 0: no rash; Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening or disabling; Grade 5: Death related to rash.
Same participant may be counted in more than one reported categories.
|
After 2 weeks of metronidazole treatment
|
|
Percentage of Participants With Erlotinib Associated Rash Stratified by Severity Grade at Week 4
Time Frame: After 4 weeks of metronidazole treatment
|
Severity of the rash was evaluated semi-quantitatively using the scale of CTCAE v3.0.
Grade 0: no rash; Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening or disabling; Grade 5: Death related to rash.
Same participant may be counted in more than one reported categories.
|
After 4 weeks of metronidazole treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Anti-Bacterial Agents
- Protein Kinase Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- Erlotinib Hydrochloride
- Metronidazole
Other Study ID Numbers
Other Study ID Numbers
- ML21308
- 2007-002895-32 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.